Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis

Prior treatment

• Patient with evidence of erythrodermic, pustular, predominantly guttate psoriasis, or drug-induced psoriasis.
• Patient who plans to receive a live or live-attenuated vaccine during the study and up to 4 weeks or 5 half-lives (of the study product), whichever is longer, after the last study product administration.
• Patient with known or suspected hypersensitivity to bimekizumab or any component of the investigational product, including any nonmedicinal ingredient, or component of the container.
• Patient who has received any marketed or investigational biological agent, except anti-IL23 agents, within 12 weeks or 5 half-lives (whichever is longer) prior to Day 1.
• Patient who has received treatment with bimekizumab prior to Day 1.

Other illness

• Patient with any known clinically significant medical condition or presence of a skin or rheumatologic disease that would, in the opinion of the investigator, put the patient at undue risk or interfere with the interpretation of study results.
• Patient with an active infection (except common cold) that would place them at increased risk, a recent serious infection, or a history of opportunistic, recurrent, or chronic infections.
• Patient with a diagnosis of inflammatory bowel disease (Crohn's disease or ulcerative colitis).

Other

• Female who is breastfeeding, pregnant, or who is planning to become pregnant during the study or within 4 months after the last study product administration.

• Male or female patient 18 years of age or older at the time of consent.
• Patient with a history of psoriasis vulgaris and PsA (as determined by the investigator) for ≥ 6 months prior to the screening visit.
• Patient with moderate-to-severe psoriasis vulgaris before initiating treatment with an anti-IL23 agent.
• Patient with an inadequate skin response to at least 12 weeks treatment with an anti-IL23 agent for the treatment of psoriasis vulgaris as defined by a PGA ≥ 2 and plaque psoriasis covering ≥ 1% of total BSA (excluding palms and soles) at the screening and Day 1 visits.
• Patient with active PsA as defined by ≥ 1 joint that is tender (TJC68) and/or swollen (SJC66) at Day 1.